Literature DB >> 26197868

Lung cancer: developments, concepts, and specific aspects of the new WHO classification.

Iver Petersen1, Arne Warth2,3.   

Abstract

INTRODUCTION: Diagnostic methods and algorithms for the diagnosis of pulmonary neoplasms have considerably changed over the recent years. Based on large-scale molecular characterization studies and the development of targeted therapies, precise morphological, immunohistochemical, and molecular pathological tumor subtyping is now of utmost importance for evidence-based treatment decisions. Changes of diagnostic concepts initially referred to biopsies and cytology specimens but are now also transferred to resection specimens.
METHODS: This review is focused on recent developments in morphological and immunohistochemical subtyping of pulmonary neoplasms and concepts of tumor progression. It also provides perspectives on relevant changes of diagnostic concepts within the context of the new WHO classification.
CONCLUSION: It becomes apparent that a three-step diagnostic concept based on morphology, immunohistochemistry, and molecular pathology is important to meet the requirements of an increasingly more complex, interdisciplinary care of lung cancer patients and to allow for reliable, clinically meaningful tumor diagnoses.

Entities:  

Keywords:  Classification; Diagnosis; Immunohistochemistry; Lung cancer; Molecular pathology

Mesh:

Year:  2015        PMID: 26197868     DOI: 10.1007/s00432-015-2004-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  49 in total

1.  Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification.

Authors:  Arne Warth; Judith Cortis; Ludger Fink; Annette Fisseler-Eckhoff; Helene Geddert; Thomas Hager; Klaus Junker; Gian Kayser; Julia Kitz; Florian Länger; Alicia Morresi-Hauf; German Ott; Iver Petersen; Albrecht Stenzinger; Alex Soltermann; Saskia Ting; Verena Tischler; Ekkehard Vollmer; Philipp A Schnabel; Wilko Weichert
Journal:  Virchows Arch       Date:  2012-06-23       Impact factor: 4.064

2.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

Authors:  William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  Multidirectional differentiation of Achaete-Scute homologue-1-defined progenitors in lung development and injury repair.

Authors:  Yan Li; R Ilona Linnoila
Journal:  Am J Respir Cell Mol Biol       Date:  2012-08-09       Impact factor: 6.914

4.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

Review 5.  Functional facets of the pulmonary neuroendocrine system.

Authors:  R Ilona Linnoila
Journal:  Lab Invest       Date:  2006-05       Impact factor: 5.662

Review 6.  [Novel morphological and molecular aspects of lung cancer].

Authors:  A Warth; A Stenzinger; W Weichert
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

7.  Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance.

Authors:  E Brambilla; D Moro; D Veale; P Y Brichon; P Stoebner; B Paramelle; C Brambilla
Journal:  Hum Pathol       Date:  1992-09       Impact factor: 3.466

8.  Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe.

Authors:  M L Janssen-Heijnen; J W Coebergh
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

9.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

10.  The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Camelia S Sima; Valerie W Rusch; Andre L Moreira; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2013-11-01       Impact factor: 7.842

View more
  22 in total

1.  FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.

Authors:  C Feng; F Yang; J Wang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

2.  CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development.

Authors:  Yo-Taro Shirai; Anna Mizutani; Saori Nishijima; Masafumi Horie; Chisato Kikuguchi; Olga Elisseeva; Tadashi Yamamoto
Journal:  Oncogene       Date:  2018-12-10       Impact factor: 9.867

Review 3.  [Pathology of lung cancer].

Authors:  D Theegarten; T Hager
Journal:  Radiologe       Date:  2016-09       Impact factor: 0.635

4.  Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients.

Authors:  Ming-Yue Liu; Xi-Qing Li; Tian-Hui Gao; Yao Cui; Ning Ma; Yun Zhou; Guo-Jun Zhang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

5.  Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells.

Authors:  I Yuan; Chi-Ting Horng; Vincent Chin-Hung Chen; Chun-Hung Chen; Li-Jeng Chen; Tsai-Ching Hsu; Bor-Show Tzang
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

Review 6.  [Grading of soft tissue and bone sarcomas].

Authors:  I Petersen; E Wardelmann
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

7.  CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression.

Authors:  Hang Peng; Wan Zhang; Huanhuan Dong; Jialan Yuan; Yankun Li; Fanni Li; Daping Yu; Yingjie Guan; Feng Zhang
Journal:  Int J Biol Sci       Date:  2022-06-13       Impact factor: 10.750

8.  Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis.

Authors:  Xin Luo; Xiao Zang; Lin Yang; Junzhou Huang; Faming Liang; Jaime Rodriguez-Canales; Ignacio I Wistuba; Adi Gazdar; Yang Xie; Guanghua Xiao
Journal:  J Thorac Oncol       Date:  2016-11-04       Impact factor: 15.609

9.  Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.

Authors:  Jianlin Xu; Yanwei Zhang; Bo Jin; Tianqing Chu; Xue Dong; Haitang Yang; Dan Wu; Yuqing Lou; Xueyan Zhang; Huiming Wang; Baohui Han
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-04       Impact factor: 4.553

10.  Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery.

Authors:  Baoqian Zhai; Jia Chen; Jiacheng Wu; Lei Yang; Xiaoli Guo; Jingjing Shao; Hong Xu; Aiguo Shen
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.